Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
98 EUR | -1.01% | -.--% | +2.08% |
03/06 | Eli Lilly: encouraging data for olomorasib | CF |
03/06 | Structure Therapeutics' obesity drug meets main goal in mid-stage study | RE |
Business Summary
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100.0
%
| 28,541 | 100.0 % | 34,124 | 100.0 % | +19.56% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
63.9
%
| 18,190 | 63.7 % | 21,791 | 63.9 % | +19.80% |
Europe
18.1
%
| 4,299 | 15.1 % | 6,175 | 18.1 % | +43.62% |
Other Foreign Countries
8.6
%
| 2,852 | 10.0 % | 2,946 | 8.6 % | +3.30% |
Japan
4.9
%
| 1,747 | 6.1 % | 1,673 | 4.9 % | -4.28% |
China
4.5
%
| 1,453 | 5.1 % | 1,540 | 4.5 % | +5.98% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17/21/17 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/23/16 |
Alonzo Weems
CMP | Compliance Officer | - | 01/97/01 |
Chief Tech/Sci/R&D Officer | 50 | 01/18/01 | |
Corporate Officer/Principal | - | 01/05/01 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
- | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
Juan Luciano
BRD | Director/Board Member | 62 | 01/16/01 |
William Kaelin
BRD | Director/Board Member | 66 | 04/12/04 |
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01/16/01 |
Director/Board Member | 52 | 12/11/12 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01/13/01 |
Karen Walker
BRD | Director/Board Member | 62 | 01/18/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 950,770,386 | 948,828,714 ( 99.80 %) | 365,000 ( 0.0384 %) | 99.80 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2,548,145 | 6.25% | 147,792,410 $ |
8,084,411 | 6.83% | 50,293,848 $ | |
PROQR THERAPEUTICS N.V. 16.55% | 13,371,562 | 16.55% | 26,208,262 $ |
4,000,000 | 9.40% | 20,920,000 $ | |
21,776,804 | 7.60% | 11,332,213 $ | |
AC IMMUNE SA 3.64% | 3,615,328 | 3.64% | 8,279,101 $ |
125,405 | 1.81% | 1,218,937 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Kinsale Financial Services
| |
Lilly Nederland Finance BV
Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The company is based in Utrecht, Netherlands. |
Miscellaneous Commercial Services
|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Eli Lilly (Suisse) SA
| |
Lilly Global Nederland Holdings BV
Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The company is based in Utrecht, Netherlands. |
Financial Conglomerates
|
Eli Lilly Vostok SA
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.34% | 60TCr | |
-5.74% | 35TCr | |
+17.79% | 32TCr | |
+3.37% | 28TCr | |
+16.47% | 24TCr | |
+9.26% | 21TCr | |
-5.07% | 21TCr | |
+6.74% | 16TCr | |
+1.81% | 16TCr |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
- Company Eli Lilly and Company